Amsterdam-based myTomorrows, a health tech firm facilitating patient access to pre-approval treatments, has gained significant backing with a new €25 million investment. This support originates from Avego Healthcare Capital, known for its focus on innovative healthcare ventures. myTomorrows endeavors to break the barriers hindering patient access to therapies still under development. The company’s AI-driven platform seeks to streamline this process, aligning with its objective to reach underserved patients. A stronger global presence is anticipated following this financial injection.
Earlier reports on myTomorrows showcased its consistent efforts since 2012 to connect patients and healthcare innovations. While prior expansions focused on building initial connections and systems, the current investment highlights a strategic shift towards technological enhancement and global influence. This phase signifies not only a continuation of previous endeavors but also a targeted drive for technological sophistication and broader reach.
How will the new funds change myTomorrows?
The infusion of capital is slated to elevate the company’s global market operations and intensify the development of its AI-based platform. This platform is crucial for linking patients, physicians, trial sites, and BioPharma entities effectively. The financial support will also bolster collaborations in the pharmaceutical sector, enhancing clinical progressions and augmenting the utilization of real-world data to obtain regulatory insights.
“This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow’s therapies,” remarked Michel van Harten, CEO of myTomorrows.
Avenue’s investment facilitates a pivotal step in myTomorrows’ commitment to amplifying patient access.
Why connect patients and BioPharma through AI?
The core mission of myTomorrows is to optimize patient access to pre-approval treatments, including clinical trials and expanded access programs (EAPs). The company’s centralized platform merges AI technology with human expertise to create individualized solutions, eradicating the primary obstacles to patient access. This platform fosters collaboration between various healthcare actors.
“We envisioned a better way to connect patients with promising therapies,” said Ronald Brus, Founder and Board Member of myTomorrows, reflecting on the company’s creation.
The integration of technology and human oversight is pivotal in advancing myTomorrows’ agenda.
In addition to managing clinical trial recruitment, myTomorrows supports BioPharma companies in gathering real-world data crucial for developing new treatments. For trial locations, the firm introduces a referral management system, offering enhanced visibility and real-time updates. These efforts are geared towards empowering patients, making their access to new therapies more transparent and efficient.
By improving the pathway to treatment discovery through technological advancements, myTomorrows strengthens its impact in the global health domain. The company’s headquarters in Amsterdam, alongside its New York office, stands as vital operational centers as it enhances its reach worldwide. Having supported over 16,900 patients and 2,800 physicians, the company has made significant strides in distributing innovation across 133 countries.
myTomorrows’ ongoing expansion underscores its resilience and dedication to transforming healthcare access. The company’s partnerships with entities like Avego Healthcare Capital position it as a significant player in the innovative healthcare landscape. With a focus on technology and strategic collaboration, myTomorrows continues to pursue avenues that widen the reach of emerging medical treatments to patients globally.
